Tuesday, July 28, 2026

BTC $63,168 ▼ 0.83%

LIVE

ADA$0.155−0.59%ETH$1,874−0.87%LINK$8.32−0.59%SOL$73.19−1.28%BTC$63,168−0.83%XRP$1.06−0.62%S&P 5007,413+0.02%Nasdaq24,932−0.18%Dow52,210+0.51%RUT2,948+0.62%TNX4.64%−0.81%TYX5.13%−0.72%FVX4.40%−0.66%IRX3.80%−0.21%VIX18.67+0.48%GOLD$4,057.50−0.48%SILVER$57.72−1.69%OIL$81.82−0.96%DXY101.47−0.07%NVDA$196.51−4.99%AAPL$336.91+1.17%TSLA$309.22−1.22%META$593.87−0.22%MSFT$389.10+1.94%AMZN$231.39−0.31%GOOGL$326.56+2.13%Fear & Greed29 — FearADA$0.155−0.59%ETH$1,874−0.87%LINK$8.32−0.59%SOL$73.19−1.28%BTC$63,168−0.83%XRP$1.06−0.62%S&P 5007,413+0.02%Nasdaq24,932−0.18%Dow52,210+0.51%RUT2,948+0.62%TNX4.64%−0.81%TYX5.13%−0.72%FVX4.40%−0.66%IRX3.80%−0.21%VIX18.67+0.48%GOLD$4,057.50−0.48%SILVER$57.72−1.69%OIL$81.82−0.96%DXY101.47−0.07%NVDA$196.51−4.99%AAPL$336.91+1.17%TSLA$309.22−1.22%META$593.87−0.22%MSFT$389.10+1.94%AMZN$231.39−0.31%GOOGL$326.56+2.13%Fear & Greed29 — Fear

Tag

Regeneron

1 article

U.S. Equities70d ago

Regeneron Rises 3.4% on Eye Drug Trial Win; Mobileye Gains on $1.5B Auto Deal

Regeneron's geographic atrophy treatment met primary endpoint in Phase 3 trial while Mobileye landed multi-year European automaker contract